|
Volumn 4, Issue 3, 2000, Pages 217-223
|
Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy
a a a a a a a a a a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
COMPLEMENTARY DNA;
FLUCYTOSINE;
MONOCLONAL ANTIBODY;
PROSTATE SPECIFIC MEMBRANE ANTIGEN;
T LYMPHOCYTE RECEPTOR;
VIRUS VECTOR;
ANTIGEN EXPRESSION;
CONFERENCE PAPER;
ENHANCER REGION;
GENE EXPRESSION;
GENE TARGETING;
GENE THERAPY;
GENE TRANSFER;
HUMAN;
HUMAN CELL;
MALE;
NONHUMAN;
PRIORITY JOURNAL;
PROMOTER REGION;
PROSTATE CANCER;
RETROVIRUS;
ANIMALS;
ANTIBODIES, NEOPLASM;
ANTIGENS, NEOPLASM;
ANTIGENS, SURFACE;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CARBOXYPEPTIDASES;
ENHANCER ELEMENTS (GENETICS);
ENZYME INHIBITORS;
FEMALE;
GENE THERAPY;
GLUTAMATE CARBOXYPEPTIDASE II;
HUMANS;
MALE;
PRODRUGS;
PROMOTER REGIONS (GENETICS);
PROSTATIC NEOPLASMS;
RECEPTORS, ANTIGEN, T-CELL;
TUMOR CELLS, CULTURED;
|
EID: 0033756266
PISSN: 10915362
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
Times cited : (25)
|
References (21)
|